3/31/2016 | CV | Acquisition of Affymetrix a make-whole change under 4% convertibles
|
10/29/2015 | BK | Affymetrix closes $100 million five-year revolving credit facility
|
10/21/2013 | BK | Affymetrix amends facility for new term loans, revolver, cuts pricing
|
9/5/2013 | CV | Market Commentary: Cubist's two new tranches add on debut; Liberty exchangeable softens; Affymetrix slips
|
9/4/2013 | CV | Market Commentary: New Liberty exchangeable expands on hedge; Cubist upsizes, tightens talk; Navistar slips
|
8/1/2013 | CV | Market Commentary: ViroPharma convertibles add on hedge; Trinity contracts; ArcelorMittal mandatories flat
|
12/3/2012 | CVLM | Affymetrix calls remaining $3.9 million of 3.5% convertible notes
|
6/20/2012 | CV | New Issue: Affymetrix prices $105 million seven-year convertibles at 4%, up 25%
|
6/20/2012 | CV | Market Commentary: New Affymetrix mixed; Navistar unmoved by poison pill; L-3, United Technologies better
|
6/19/2012 | CV | Market Commentary: Revised price talk makes planned Affymetrix cheaper; DryShips expands; K-V Pharma drops
|
6/19/2012 | CV | Affymetrix's $105 million seven-year convertibles see revised talk of 3.75%-4% coupon, up 25%
|
6/18/2012 | BK | Affymetrix $85 million term loan expected at Libor plus 500 bps
|
6/18/2012 | CV | Affymetrix plans $105 million seven-year convertibles to yield 3.25%-3.75%, up 27.5%-32.5%
|
6/18/2012 | CV | Market Commentary: Affymetrix to price $105 million convertibles; Royal Gold extends gains; InterDigital adds
|
5/31/2012 | CVHYPF | Affymetrix files $200 million shelf covering debt, preferreds, stock
|
5/31/2012 | BK | Affymetrix upsizes credit facility commitment to $100 million
|
5/4/2012 | BK | Affymetrix plans $90 million credit facility for eBioscience purchase
|
3/6/2012 | CVLM | Affymetrix settles tenders for 96% of its 3.5% convertibles in offer
|
2/3/2012 | CVLM | Affymetrix begins tender offer for $95.47 million 3.5% convertibles
|
1/25/2012 | CVLM | Affymetrix to tender for $95.5 million 3.5% convertibles in settlement
|
1/25/2012 | BK | Affymetrix anticipates acquisition financing restructuring
|
1/10/2012 | BK | Affymetrix delays acquisition close again to work on debt, litigation
|
12/30/2011 | BK | Affymetrix delays acquisition close due to work on debt financing
|
12/30/2011 | CV | Affymetrix convertibles holder sues over eBioscience acquisition
|
12/8/2011 | BK | Market Commentary: Barrington breaks; SuperMedia dips; Fidelity National ups deadline; Michaels updates talk
|
12/8/2011 | BK | Affymetrix launches $190 million facility at Libor plus 600 bps
|
11/30/2011 | BK | Affymetrix plans $190 million facility for eBioscience purchase
|
1/12/2011 | CVLM | Affymetrix buys back additional $53 million 3.5% convertible notes
|
10/27/2010 | CVLM | Affymetrix buys back $72 million 3.5% convertibles for $66.9 million
|
7/21/2010 | CVLM | Affymetrix repurchases $95.8 million of 3.5% convertibles at discount
|
7/7/2010 | CV | Market Commentary: FTI Consulting richens despite revised outlook; Affymetrix steady; EMC gains after upgrade
|
5/29/2009 | CV | Affymetrix buys back $69.1 million in 3.5% convertible notes due 2038
|
11/11/2008 | SS | Affymetrix to acquire Panomics for $73 million
|
7/25/2008 | CV | Market Commentary: Affymetrix down on quarterly loss; Amgen steady pre-earnings; Countrywide bondholders eye angles
|
12/13/2007 | CV | Affymetrix greenshoe lifts 3.5% convertibles due 2038 to $316.25 million
|
11/15/2007 | CV | Market Commentary: Avery Dennison opens higher; Freeport-McMoRan, Newmont give back gains; Countrywide, Fannie Mae plunge
|
11/14/2007 | CV | New Issue: Affymetrix prices upsized $275 million 3.5% convertibles, up 39%
|
11/14/2007 | CV | Market Commentary: Affymetrix, Mylan rich and up; Freeport-McMoRan, Newmont up with metals; AMR mixed
|
11/13/2007 | CV | Affymetrix prices upsized $275 million convertibles at 3.5%, up 39%
|
11/13/2007 | CV | Market Commentary: E*Trade rebounds; Countrywide Financial up; AMR continues to fly; Yahoo!, Intel lead techs
|
7/25/2007 | CV | Convertible analyst Berkman identifies safe harbors in choppy market seas
|
11/15/2006 | BT | Affymetrix highlights product scalability, growth of molecular diagnostics business at conference
|
10/25/2006 | BT | Affymetrix reports third-quarter net loss of $14.2 million
|
9/18/2006 | BT | Affymetrix signs translational medicine agreement in China
|
9/13/2006 | BT | Affymetrix to consolidate operations as part of restructuring
|
9/7/2006 | BT | Affymetrix announces new collaborations in genotyping division
|
9/7/2006 | BT | Affymetrix, Partners HealthCare to develop microarray diagnostics
|
8/30/2006 | BTCVDD | Affymetrix cures default on 0.75% convertibles with filing of restated financials
|
8/28/2006 | BTCVDD | Affymetrix receives default notice on 0.75% convertibles for failure to file 10-Q
|
8/18/2006 | BT | Affymetrix litigation with Illumina gets Markman order
|
8/17/2006 | BT | Affymetrix to request hearing for Nasdaq non-compliance letter
|
7/31/2006 | BT | Affymetrix reports $10.1 million second quarter GAAP net loss; plans to focus on reducing operating costs
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
7/18/2006 | BT | Affymetrix plans to introduce genotyping product in early 2007
|
6/27/2006 | BT | Epigenomics licenses microarray technology from Affymetrix
|
6/21/2006 | BT | Invitrogen obtains patents to sell Affymetrix's microarrays
|
6/21/2006 | BT | Market Commentary: Cell Therapeutics gains on equity financing; Arena higher on data; MedImmune airs $1 billion bond deal
|
4/21/2006 | BT | Affymetrix reiterated at sell by Merrill
|
4/21/2006 | BT | Market Commentary: Omrix settles above water but on deep-discount pricing; Affymetrix plunges 14%; Genitope gains 3%
|
4/5/2006 | BT | Affymetrix, Abbott sign licensing deal
|
3/27/2006 | BT | Affymetrix announces new ChIP-on-chip array product line
|
3/9/2006 | BT | Merrill reiterates Affymetrix at sell
|
2/28/2006 | BT | Affymetrix plans increased production of Mapping Array Sets
|
2/7/2006 | BT | Affymetrix, Iconix collaborate to develop means of assessing drug toxicity
|
1/27/2006 | BT | Affymetrix reiterated at sell by Merrill
|
1/25/2006 | BT | Gene Logic extends agreement with Affymetrix
|
1/6/2006 | BT | Market Commentary: Affymetrix lower, Millennium up on guidance; amid rotation into small caps Amgen, Genentech slide
|
1/6/2006 | CV | Market Commentary: Convertibles market moves mostly in-line, dollar neutral; Best Buy, Cephalon gain; Affymetrix drops
|
1/6/2006 | BT | Affymetrix maintained by Merrill at sell
|
12/20/2005 | BT | Affymetrix releases GeneChip assay for mitochondrial DNA analysis
|
12/14/2005 | BT | Merrill reinstates Affymetrix at sell rating
|
10/21/2005 | BT | Market Commentary: Electro-Optical delays IPO again; Jerini IPO scheduled for Oct. 24 week; Affymetrix off; Cephalon higher
|
7/7/2005 | BT | Market Commentary: Accentia delays IPO on positive news; Salix takes off; Millipore gains; Sepracor off; Amgen soars
|
5/20/2004 | CV | Market Commentary: Airline paper cheapens further, despite rise in stocks; Guilford shelf uplifts holders of rich bonds
|
1/20/2004 | CV | Affymetrix to redeem 43/4% convertibles
|
12/10/2003 | CV | Affymetrix sells $100 million convertible at 0.75%, up 28%
|
12/10/2003 | CV | Affymetrix calls 5% convertibles
|
12/9/2003 | CV | Market Commentary: Another $2.575 billion of deals; Akamai, Emulex both reoffered at 98
|
12/9/2003 | CV | Affymetrix $100 million convertible talked at 0.5-1.0%, up 23-28%
|
12/8/2003 | CV | Affymetrix plans $100 million convertible to redeem old issues
|
12/8/2003 | CV | Market Commentary: Issuers unwrap $1.73 billion of new paper and more set to come this week, this month
|
4/4/2003 | CV | Market Commentary: Yahoo! overnighter meets few cheers; AES plan lifts power group; warning crushes Affymetrix
|
3/31/2003 | CV | Millennium may add sweetener to discourage exercise of upcoming put
|
1/30/2003 | CV | Market Commentary: Micron trading lighter as outright buyers hold on; several drug issues gain
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|